Metabolomics leader Olaris, Inc. has secured a strategic investment from Bruker Corporation (Nasdaq: BRKR), a global leader in analytical instrumentation and diagnostics solutions. The undisclosed investment, part of Olaris' Series B-1 funding round, will support the continued development and commercialization of the company's proprietary metabolomics platform.
The Framingham, Massachusetts-based precision medicine company leverages machine learning and metabolite biomarker discovery to improve disease diagnosis, treatment selection, and patient monitoring. This partnership specifically aims to apply Bruker's cutting-edge nuclear magnetic resonance (NMR) expertise to facilitate the expansion of Olaris' diagnostic product portfolio.
"We are thrilled to have Bruker as a strategic investor and partner," said Dr. Elizabeth O'Day, CEO and Founder of Olaris. "Bruker's deep expertise in NMR and commitment to innovation align with our mission to transform how we understand and treat disease. This collaboration strengthens our ability to bring impactful solutions to patients faster."
Advancing Metabolomics-Based Diagnostics
Olaris recently launched myOLARIS-KTdx, a non-invasive urine-based laboratory developed test (LDT) for the surveillance of kidney graft injury. The assay guides clinical management throughout post-transplant care by using NMR to apply non-uniform sampling, allowing faster multidimensional metabolite detection without sacrificing resolution.
The investment from Bruker underscores growing recognition of metabolomics-based panels' potential to unlock critical insights into disease biology and treatment response. With this support, Olaris plans to expand its commercial partnerships and advance its diagnostic pipeline.
Dr. Falko Busse, President of the Bruker BioSpin Group, expressed enthusiasm about the partnership: "Olaris has developed a powerful platform for discovering actionable metabolomic biomarkers. We are excited to support their vision and collaborate on driving new applications of metabolomics in precision health."
The myOLARIS Platform
The company's proprietary myOLARIS platform combines metabolomics, machine learning, and biology to uncover clinically impactful biomarkers. This approach aims to fundamentally change how diseases are treated and diagnosed by identifying metabolic signatures that can predict treatment response and disease progression.
The technology's application in kidney transplant monitoring represents just one potential use case. Metabolomics offers unique advantages in diagnostics by capturing the downstream effects of genetic, environmental, and lifestyle factors, providing a comprehensive snapshot of a patient's physiological state.
Bruker's investment reflects the growing importance of metabolomics in the precision medicine landscape. As a world leader in NMR technology, Bruker brings valuable expertise that complements Olaris' biomarker discovery and machine learning capabilities.
The collaboration between these two companies highlights an important trend in precision medicine: the integration of advanced analytical technologies with computational approaches to develop more accurate and personalized diagnostic tools.
